1. Introduction
===============

The prevalence of obesity has increased dramatically as a result of our modern lifestyle and is one of the most important targets of public health programs [@B1]. Accumulating evidence derived from both clinical and experimental studies highlight the association of obesity with a number of chronic diseases such as type II diabetes mellitus (T2DM), atherosclerosis and cardiovascular disease (CVD). T2DM is a problem not only in developed countries but is also becoming an urgent problem in developing countries owing to the worldwide increase in obesity [@B2]. Therefore, there is considerable effort to understand the underlying biology of these disease states and to identify the contributing risk factors.

The clustering of CVD risk factors, most notably the simultaneous presence of obesity, T2DM, dyslipidemia, and hypertension was recognized as an important pathophysiological state [@B3]-[@B5]. The coexistence of these diseases has been termed the metabolic syndrome (MS). Insulin resistance (IR) is well known to be a key feature of MS, and is strongly associated with excess adiposity, especially in the intra-abdominal region. Individuals with MS are at increased risk for the development of CVD and other diseases related to plaque formation in artery walls, resulting in stroke and peripheral vascular disease. Because the prevalence of these diseases is increasing, high throughput assessment of disease states accompanied with obesity or MS are important issues from the public health point of view.

Excess white adipose tissue (WAT) is linked to obesity-related health problems. It is also recognized that obesity is accompanied by chronic, low-level inflammation of WAT [@B6], [@B7]. Inflammation has been considered to be associated with the development of IR and MS [@B8]. Recently, WAT has been recognized as an important endocrine organ that secretes a wide variety of biologically active adipokines [@B9]-[@B11]. Since some of these adipokines greatly influence insulin sensitivity, glucose metabolism, inflammation and atherosclerosis, they may provide a molecular link between increased adiposity and the development of T2DM, MS and CVD. The signals from WAT are thought to directly connect with IR and inflammation. It is expected, therefore, that circulating levels of adipokines may be useful as biomarkers to evaluate the risk of other disease states associated with obesity.

This review describes the usefulness and clinical significance of circulating adipokine levels. First, I focused on three representative adipokines associated with IR, namely adiponectin, retinol binding protein 4 (RBP4) and resistin. Next, I discuss the inflammation-related markers such as tumor necrosis factor (TNF) α, interleukin (IL)-6 and C-reactive protein (CRP). Because leptin has not been recognized directly to be related with IR and inflammation, description of this adipokine was excluded. Finally, I have summarized the significance of other molecules, followed by a brief discussion for future research.

2. Adipose tissue as a secretory organ
======================================

In 1993, it was discovered that TNFα expression was up-regulated in WAT of obese mice [@B12]. The role of WAT as a hormone-producing organ became well recognized in 1994 with the discovery of leptin as an adipocyte-secreted protein [@B13]. Systemic analysis of the active genes in WAT, by constructing a 3\'-directed complementary DNA library, revealed a high frequency of genes encoding secretory proteins. Of the gene group classified by function, approximately 20--30% of all genes in WAT encode secretory proteins [@B14].

In adults, most organ systems have reached their final size and are programmed to be maintained at steady state. However, WAT is unique because of its almost unlimited expansion potential. Thus, WAT can become one of the largest organs in the body, and the total amount of an adipokine secreted from WAT may affect whole-body homeostasis. WAT contains various types of cells that include preadipocytes, adipocytes and stromal vascular cells. Moreover, bone marrow-derived macrophages home to WAT in obesity [@B6], [@B7]. The massive increase in fat mass leads to a dysregulation of circulating adipokine levels that may have pathogenic effects associated with obesity. Thus, dysregulated secretion of adipokines, not only from adipocytes but also from macrophages in WAT, will contribute to the pathogenesis of obesity by triggering IR and systemic inflammation (Fig. [1](#F1){ref-type="fig"}). It is expected, therefore, that circulating levels of adipokines can be used as a high-throughput biomarker to assess obesity-related health problems.

3. Adiponectin
==============

Adiponectin is the most abundantly expressed adipokine in WAT [@B14]. The average levels of adiponectin in human plasma are 5--10 μg/ml [@B15]. Adiponectin is a multifunctional protein that exerts pleiotropic insulin-sensitizing effects. It lowers hepatic glucose production [@B16] and increases glucose uptake and fatty acid oxidation in skeletal muscle [@B17]. Moreover, adiponectin may possess anti-atherogenic properties by inhibiting the expression of adhesion molecules and smooth muscle cell proliferation, as well as suppressing the conversion of macrophages to foam cells [@B18], [@B19]. An anti-inflammatory role of adiponectin has also been reported [@B20].

A number of studies reported the significance of circulating levels of adiponectin (Table [1](#T1){ref-type="table"}). Unlike most adipokines, adiponectin mRNA in WAT and serum levels are decreased in obesity [@B21]. Adiponectin is the only adipokine that is known to be down-regulated in obesity. Plasma concentrations are negatively correlated with body mass index (BMI) [@B15]. A longitudinal study in primates suggests that adiponectin decreases with weight gain as animals become obese [@B22]. In contrast, weight loss results in significant increases in circulating adiponectin levels [@B23], [@B24]. In addition to the association with whole-body fat mass, adiponectin levels differ with the distribution of body fat. Plasma levels of adiponectin exhibit strong negative correlations with intra-abdominal fat mass [@B25]. Visceral, but not subcutaneous abdominal fat, was reported to be inversely associated with plasma adiponectin levels in healthy women [@B26]. A low waist to hip ratio has been reported to be associated with high levels of plasma adiponectin independent of the body fat percentage [@B27].

Plasma adiponectin concentrations are lower in people with T2DM than in BMI-matched controls [@B28]. The plasma concentrations have been shown to correlate strongly with insulin sensitivity, which suggests that low plasma concentrations are associated with IR [@B29]. In a study of Pima Indians, a population that has one of the highest prevalence of obesity, IR and T2DM, individuals with high adiponectin levels were less likely to develop T2DM than those with low concentrations [@B30]. The high adiponectin concentration was, therefore, a predictive marker for the development of T2DM. Plasma concentrations of adiponectin are also reported to be associated with components of MS. High plasma concentrations of adiponectin were found to be related to an advantageous blood lipid profile [@B31], [@B32]. Plasma adiponectin levels are decreased in hypertensive humans, irrespective of the presence of IR [@B33]. Endothelium-dependent vasoreactivity is impaired in people with hypoadiponectinemia [@B34], which might be one of the mechanisms involved in hypertension in visceral obesity. A reciprocal association between CRP and adiponectin mRNA levels was reported in human WAT, suggesting that hypoadiponectinemia appears to contribute to low-grade systemic chronic inflammation [@B35]. All these mechanisms may underlie the protective effects against the progression of atherosclerosis of adiponectin. A recent study revealed that adiponectin may function as a biomarker for MS, even in childhood obesity [@B36]. Collectively, adiponectin has been recognized as a key molecule in MS and has the potential to become a clinically relevant parameter to be measured routinely at general medical check ups.

Plasma concentrations of adiponectin are also known to be lower in people with CVD than in controls, even after matching for BMI and age [@B37]. A case-control study performed in Japan revealed that the people with hypoadiponectinemia with the plasma levels less than 4 μg/ml had increased risk of CVD and multiple metabolic risk factors, indicating that hypoadiponectinemia is a key factor in MS [@B38]. Retrospective case-control studies have demonstrated that patients with the highest levels of adiponectin have a dramatically reduced 6-year risk of myocardial infarction compared with case controls with the lowest adiponectin levels, and this relationship persists even after controlling for family history, BMI, alcohol, history of diabetes and hypertension, hemoglobin A1c, CRP, and lipoprotein levels [@B39]. An inverse relationship between serum adiponectin levels and the intima media thickness of common carotid arteries was also reported [@B40]. These clinical studies clearly indicate that hypoadiponectinemia is a strong risk factor for CVD.

Although the above studies support the notion that adiponectin would protect against vascular diseases, recent epidemiological studies have failed to support this notion [@B41]-[@B51]. A recent prospective study reported adiponectin levels were not significantly associated with future secondary CVD events [@B41]. Thus, measurement of adiponectin may add no significant value to risk stratifications in patients with incident CVD, and effects of adiponectin may be more of importance in the early phases of atherosclerosis. Kistorp et al. reported that adiponectin was positively related to increased mortality in patients with chronic heart failure [@B42]. These authors suspect that the high adiponectin concentrations may reflect a wasting process in subjects with increased risk of death. Pilz et al. reported that high adiponectin levels predict all-cause, cardiovascular and noncardiovascular mortality [@B50]. A recent study also reported that a high adiponectin level was a significant predictor of all-cause and CVD mortality [@B51]. These authors hypothesized that a counter-regulatory increase in adiponectin occurs, which represents a defense mechanism of the body against cardiovascular alterations and a pro-inflammatory state associated with CVD. Thus, yet-unknown mechanisms may underlie the association between adiponectin and the risk of death, the prognostic value of adiponectin remains unresolved. Further prospective studies will be required to provide conclusive results about the association of adiponectin and mortality. It is also necessary to understand the underlying molecular mechanisms of elevated adiponectin concentrations in these disease states.

It must be highlighted that several physiological factors affect the circulating levels of adiponectin. First, aging, gender and puberty have effects on circulating adiponectin levels [@B52], [@B53]. An age-associated elevation of plasma adiponectin levels has been reported [@B51], [@B54]. Plasma adiponectin levels were significantly higher in female subjects, indicative of a sex hormone affect on circulating adiponectin levels [@B51], [@B55]. Adiponectin levels tend to decrease throughout puberty, which parallels the development of IR [@B36], [@B56]. Second, the glomerular filtration rate has been recognized as a strong inverse predictor of adiponectin. The clearance of adiponectin by the kidney may have a strong influence on its concentration [@B57]. Hence, high adiponectin levels may reflect impaired renal function. Last but not least, an increased adiponectin level has been suggested to act as a compensatory mechanism to dampen inflammation. Indeed, elevated plasma adiponectin concentrations are observed in several diseases associated with inflammation: arthritis [@B58], preeclampsia [@B59], and end-stage renal disease [@B60]. All of these factors must be considered when evaluating the clinical significance of circulating adiponectin levels in MS or vascular diseases related to obesity.

Circulating adiponectin forms several different complexes in the adipocyte before being secreted into the blood [@B61]. Commercial assays measure the total plasma concentration of adiponectin. Thus, the vast majority of clinical studies published to date have evaluated correlations between total adiponectin levels and various markers of MS. The most basic form of adiponectin secreted is the trimer. Adiponectin forms two higher-ordered structures through the noncovalent binding of two trimers (hexamers) and six trimers (18mers). The native protein circulates in serum as low molecular weight (LMW) hexamers and as larger multimeric structures of high molecular weight (HMW). Of these higher-ordered structures, the 18mer (HMW) form is assumed to act beneficial against IR; the function of the hexamer (LMW) form is suggested to play a pro-inflammatory role [@B55], [@B62]. Thus, the HMW form is more strongly associated with insulin sensitivity than is total adiponectin [@B63]-[@B65]. Overall, these results suggest that the assessment of total adiponectin may be insufficient and that the analysis of the levels of the multimeric forms should be favorable to assess the significance of adiponectin.

4. Retinol binding protein 4 (RBP4)
===================================

RBP4 is a protein that is the specific carrier for retinol in the blood. It is one of a large number of proteins that solubilize and stabilize the hydrophobic and labile metabolites of retinoids in aqueous spaces in both extra- and intracellular spaces. Its physiological function appears to be to bind retinol and prevent its loss through the kidneys. RBP4, although largely produced in liver, is also made by adipocytes, with increased levels in obesity contributing to impaired insulin action [@B66]. Studies in transgenic rodent models showed overexpression of human RBP4 or injection of recombinant RBP4 induced IR in mice, whereas RBP4 knockout mice showed enhanced insulin sensitivity [@B66]. The same authors reported that high plasma RBP4 levels are associated with IR states in humans and suggested that RBP4 is an adipokine responsible for obesity-induced IR and, thus, a potential therapeutic target in T2DM [@B66], [@B67]. Since then, a number of clinical studies have been conducted to assess the significance of circulating levels of RBP4 (Table [2](#T2){ref-type="table"}).

Cho et al. reported that plasma concentrations of RBP4 were higher in people with impaired glucose tolerance (IGT) or T2DM than in people with normal glucose tolerance [@B68]. A recent cross-sectional study of 3289 middle-aged population showed that plasma RBP4 levels increased gradually with increasing numbers of MS components [@B69]. Similar to other adipokines, circulating levels of RBP4 is associated with body fat distribution rather than body weight *per se*. RBP4 was reported to be more highly correlated with waist-to-hip ratio or visceral fat areas than with BMI [@B67], [@B70], [@B71]. However, Janke et al. reported that, in human abdominal subcutaneous (sc) adipose tissue, RBP4 mRNA is down-regulated in obese women, whereas circulating RBP4 concentrations were similar in lean, overweight, and obese women [@B72]. Yao-Borengasser et al. also reported that neither sc adipose tissue RBP4 mRNA expression nor circulating RBP4 levels show any correlation with BMI [@B73]. It is not clear why such differences are present among similarly conducted human studies. These inconsistencies most likely result from differences in age, ethnicity, sample size, and assay methods used. For example, sex and age were found to be independent determinants of plasma RBP4 concentrations [@B68], [@B74]. A recent study suggested that the sandwich ELISA kit commercially available for the assessment of RBP4 may overestimate the circulating levels [@B75]. Those authors also claimed that competitive EIAs may underestimate serum RBP4 levels in the setting of IR owing to assay saturation. Thus, it is probable that the reported RBP4 associations would become clearer if more reliable assays were employed.

Two recent studies have indicated that high circulating RBP4 is associated with elevated liver fat and, presumably, hepatic insulin resistance [@B76], [@B77]. In rodents, only 20% of systemic RBP4 is produced by adipocytes, and RBP4 gene expression in adipocytes was 20% compared with expression in the liver [@B78]. Thus, it is possible that the increase in systemic RBP4 concentrations is not explained by increased RBP4 production in WAT. RBP4 is a transporter for retinol, which serves as a precursor for the synthesis of ligands for nuclear hormone receptors such as retinoid X receptor and retinoic acid receptor. Thus, circulating RBP4 can modulate metabolic pathways via these nuclear hormone receptors. Certainly, future prospective studies are needed to clarify whether a high RBP4 level plays a causal role in the development of MS, T2DM, and eventually for the development of CVD.

5. Resistin
===========

After the identification of resistin as an adipokine in 2001 [@B79], several studies have been conducted to investigate the role and significance of this molecule. Resistin was discovered as a result of a hypothesis that WAT secretes a hormone that mediates IR and that insulin sensitizing drug thiazolidinediones act by suppressing the production of this hormone. Resistin is secreted by mature adipocytes in proportion to the level of obesity and acts on insulin-sensitive cells to antagonize insulin-mediated glucose uptake and utilization in mice. Treatment of wild-type mice with recombinant resistin resulted in IR, whereas administration of an anti-resistin antibody increased insulin sensitivity in obese and insulin-resistant animals [@B79]. However, human resistin is 59% homologous at the amino acid level to the mouse molecule, a relatively low degree of sequence conservation. Moreover, in contrast to mice, human resistin is expressed at lower levels in adipocytes but at higher levels in circulating blood monocytes [@B80]. As a result, there is still uncertainty about possible relationships between serum concentrations of resistin and markers of IR (Table [3](#T3){ref-type="table"}).

The role of resistin in the pathophysiology of obesity and IR in humans is controversial. Several studies have shown positive correlations of circulating resitin levels with body fat mass [@B80], [@B81] or IR [@B82], [@B83]. However, the other studies found no relationship between resistin gene expression and body weight or insulin sensitivity [@B84]-[@B86]. These conflicting data may reflect variations in the study design and the lack of adjustment for potential confounding factors. It also seems possible that resistin is a marker for, or contributes to, IR in a specific population. The predominantly paracrine role of resistin might explain the weakness of the correlations between circulating resistin levels and some of the metabolic variables.

Two studies have shown that among the blood markers, the most significant association of the circulating resistin level was with plasma CRP [@B87], [@B88]. Thus, higher resistin levels may be a marker of systemic inflammation. Indeed, the circulating level of resistin is up-regulated in patients with rheumatoid arthritis [@B89]. The circulating resistin level is also reported to be an inflammatory marker of atherosclerosis [@B90]. Considering that the resistin concentration is elevated in the patients with severe inflammatory disease [@B91], hyperresistinemia may be a biomarker and/or a mediator of inflammatory states in humans. Overall, the resistin levels in humans are thought to correlate more closely with inflammation than with IR.

6. Inflammation-related molecules
=================================

Obesity is associated with a state of chronic, low-grade inflammation characterized by abnormal cytokine production and the activation of inflammatory signaling pathways in WAT [@B92]. Obese hypertrophic adipocytes and stromal cells within WAT directly augment systemic inflammation. Although WAT is usually populated with 5-10% macrophages, diet-induced weight gain causes a significant macrophage infiltration, with macrophages comprising up to 60% of all cells found in WAT in a rodent model [@B6]. Thus, several adipokines implicated in inflammation are cytokines which are produced by macrophages. The accumulation of WAT resident macrophages and elaboration of inflammatory cytokines have been implicated in the development of obesity-related IR. Indeed, increases in inflammatory cytokine expression by WAT are associated with a parallel increase in WAT macrophage content [@B6], [@B7], [@B93]. Thus, obesity leads to increased production of several inflammatory cytokines, which play a critical role in obesity-related inflammation and metabolic pathologies.

A number of studies have reported that several humoral markers of inflammation are elevated in people with obesity and T2DM [@B94], [@B95] (Table [4](#T4){ref-type="table"}). Pfeiffer et al. showed that men with T2DM had higher TNFα concentrations compared with nondiabetic subjects [@B96]. However, several studies reported no association between circulating levels of TNFα and insulin sensitivity [@B97], [@B98]. Since there was no arteriovenous difference with TNFα [@B99], TNFα is considered to work mainly in an autocrine or paracrine manner, where the local concentrations would be more likely to exert its metabolic effects [@B99], [@B100]. Moreover, circulating TNFα has been reported to be associated with a soluble receptor that inhibits its biological activity [@B101], suggesting that the action of TNFα is primarily a local one. Therefore, it seems unlikely that the circulating levels of TNFα would be a good biomarker to reflect the IR state of the whole body.

A considerable proportion of circulating IL-6 is derived from WAT, and WAT is estimated to produce about 25% of the systemic IL-6 in vivo [@B99]. Fasting plasma IL-6 concentrations were negatively correlated with the rate of insulin-stimulated glucose disposal in Pima Indians [@B102]. Bastard et al. reported that the IL-6 values were more strongly correlated with obesity and IR parameters than TNFα, and a very low-calorie diet induced significant decreases in circulating IL-6 levels in obese women [@B103]. Other studies have also showed that weight loss results in decreased circulating levels of IL-6 [@B104]-[@B106]. Although several reports have indicated that IL-6 plays a role in the development of IR [@B95], [@B107], some investigators have insisted that IL-6 prevents IR [@B108], [@B109]. Some of these discrepancies may be explained by the widely different characteristics of the study populations regarding age, sex, glucose tolerance status, and degree of obesity. Overall, the association of IL-6 and IR seems complex and IL-6 alone might not be an appropriate marker of IR or MS [@B110], [@B111].

IL-6 derived from visceral adipose tissue draining directly into the portal system and causes the obesity-associated rise of liver CRP production [@B112]. Although CRP was traditionally thought to be produced exclusively by the liver in response to inflammatory cytokines, emerging data indicate that CRP can also be produced by nonhepatic tissues. Adipocytes isolated from human WAT produced CRP in response to inflammatory cytokines [@B113]. Adiponectin has been suggested to play a role in modulating CRP levels. In fact, adiponectin knockout mice showed higher CRP mRNA levels in WAT compared with the wild-type mice [@B35]. Therefore, hypoadiponectinemia also appears to be responsible for a low-grade systemic chronic inflammatory state, which is closely related to high CRP levels.

Several studies have shown that CRP is more strongly associated with IR than either TNFα or IL-6 [@B110], [@B111], [@B114]. CRP has been reported to be associated with body fat and other inflammatory markers [@B86], [@B115]. Abundant evidence has accumulated to show that CRP is associated with MS and predicts T2DM and CVD events independently of traditional risk factors [@B114], [@B116]. Thus, elevated CRP levels in obesity, and the decreases associated with weight loss indicate a link between CRP and obesity-associated risks for CVD [@B104], [@B117], [@B118].

7. Chemokines: monocyte chemoattractant protein-1 and IL-8
==========================================================

Monocyte chemoattractant protein-1 (MCP-1) is a chemokine, which plays a pivotal role in the recruitment of monocytes and T lymphocytes to the sites of inflammation. MCP-1 is expressed in adipocytes and considered to be an adipokine [@B119], [@B120]. MCP-1 mediates the infiltration of macrophages into WAT in obesity and may play an important role in establishing and maintaining a proinflammatory state that predisposes to the development of IR and MS [@B121]. Macrophage infiltration into WAT is increased by the secretion of MCP-1, which is expressed by adipocytes, as well as by macrophages and other cell types, especially in obese, insulin-resistant subjects [@B122]. A number of studies have reported significantly higher circulating MCP-1 levels in obese [@B122], [@B123] or T2DM patients [@B124], [@B125]. Conversely, obese patients who lost weight showed decreased levels of MCP-1 [@B122], [@B126]. However, a recent study indicated that there was no difference in circulating MCP-1 levels between nonobese and obese subjects, when either abdominal venous or arterialized blood was analyzed [@B127]. Previous studies showed that plasma MCP-1 levels were influenced by numerous factors, including aging [@B128], hypertension [@B129], hypercholesterolemia [@B130], vascular disease [@B131], and renal failure [@B132]. Moreover, MCP-1 is also produced by other cell types, such as vascular smooth muscle cells, endothelial cells, fibroblasts, mesangial cells, and lymphocytes. Thus, undetectable conditions might have influenced the circulating MCP-1 levels, and it seems improbable that the circulating levels of MCP-1 merely reflect obesity-related disease states.

IL-8 is responsible for the recruitment of neutrophils and T lymphocytes into the subendothelial space and considered to be an atherogenic factor that leads to intimal thickening. IL-8 is produced and secreted by human adipocytes [@B133]. Plasma IL-8 levels are increased in obese subjects, linking obesity with increased cardiovascular risk [@B134]. The circulating IL-8 level is associated with obesity-related parameters such as BMI, waist circumference and CRP [@B123]. However, Herder et al. reported that, among the seven immunological mediators (IL-6, IL-18, TNFα, IL-8, MCP-1, IP-10, and adiponectin) expressed and secreted by WAT, high BMI was significantly associated with elevated circulating levels of IL-6, IL-18, and IP-10 as well as lower levels of adiponectin [@B135]. Thus, the clinical relevance of circulating levels of MCP-1 and IL-8 to predict obesity-related disease conditions is still unresolved.

8. Other molecules
==================

Plasminogen activator inhibitor-1 (PAI-1) is an important endogenous inhibitor of tissue plasminogen activator and is a main determinant of fibrinolytic activity. PAI-1 contributes to the pathogenesis of atherothrombosis and CVD. Experimental data indicate that WAT has a capacity to produce PAI-1 [@B136]. Much of the elevation of circulating levels of PAI-1 in obesity is attributable to upregulated production from WAT [@B136]-[@B138]. The increased plasma PAI-1 levels in obesity and positive correlations with visceral fat depots are reported in several studies [@B139]-[@B142]. Conversely, weight loss is associated with reduced PAI-1 activity in obese subjects [@B143]. Hyperinsulinemia caused by IR may increase both adipocyte and hepatic synthesis of PAI, which could play a role in the development of the vascular complications [@B144], [@B145].

Obesity is associated with expansion of the capillary bed in regional fat depots. Adipocytes or other cell types present in WAT secrete angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which act in an autocrine or paracrine manner within WAT but may have endocrine effects throughout the body. Serum VEGF levels were found to positively correlate with BMI [@B146], [@B147]. HGF has also been reported to be elevated in obese subjects [@B148] and elevated serum HGF in obese subjects is reduced with weight loss [@B149]. These angiogenic factors may be involved in the development of obesity-related metabolic disorders such as inflammation and CVD.

Cathepsin S was recently identified as a novel adipokine [@B150]. Cathepsin S is a cysteine protease that has the ability to degrade many extracellular elements and is involved in the pathogenesis of atherosclerosis [@B151]. Cathepsin S is secreted by adipocytes and its circulating levels are increased in obese subjects than in nonobese subjects [@B152]. Conversely, weight loss is associated with a decrease in circulating cathepsin S levels as well as WAT cathepsin S content [@B152]. Thus, cathepsin S could constitute a novel biomarker of adiposity that may be linked with enlarged WAT and may also play a role in vascular pathogenesis in obesity.

9. Conclusions
==============

Obesity is recognized as a worldwide public health problem that contributes to a wide range of disease conditions. The development of a method for convenient prediction of obesity-related health problems represents a major challenge for public policy makers facing the epidemic of obesity. WAT is an endocrine organ that communicates with other tissues via secretion of adipokines. Adipokines, which integrate metabolic and inflammatory signals are attractive candidates for predicting the risk of CVD. With obesity, the production of most adipokines is enhanced, except for the anti-inflammatory and insulin-sensitizing effector, adiponectin. Enlarged adipocytes and macrophages embedded within WAT produce more RBP4, resistin and proinflammatory cytokines, such as TNFα and IL-6. Markers of inflammation including CRP have been proposed for use in clinical practice to aid in the identification of asymptomatic patients at high risk for CVD. Thus, measurement of adiponectin and inflammatory markers could be used to assess the risk of developing CVD.

It is important to note, however, that only a limited number of adipokines are released into the bloodstream at levels that are detectable with current assays, resulting in increased circulating levels in the obese state. Some adipokines acting in a paracrine or autocrine manner may play an important role; thus, circulating levels of the adipokines may represent only spillover from WAT and may not be associated with the disease condition. Moreover, except for adiponectin, many of the adipokines are not expressed exclusively in WAT. Thus, there remains uncertainty as to the most appropriate and optimal marker for use in clinical practice. Since various WAT in different regions may have unique characteristics related to differential expression of adipokines, different types of fat distribution may offer the explanations for the discrepancies observed between different studies. Further epidemiological studies with solid clinical end points are needed to determine which combination of adipokines can be a reliable risk marker for CVD and may provide an improved method for identifying persons at risk for future cardiovascular events. Elucidation of the significance of circulating adipokines may provide a therapeutic target for adipokine-based pharmacological and/or interventional therapies in obesity and related complications.
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###### 

Clinical studies of circulating adiponectin levels

  Subjects                                 Major findings                                                                   References
  ---------------------------------------- -------------------------------------------------------------------------------- -------------------------------------
  Obese subjects                           Decreased in obese subjects                                                      Hu et al., (1996) [@B21]
                                                                                                                            Arita et al., (1999) [@B15]
  Patients with CVD                        Decreased in patients with CVD                                                   Ouchi et al., (1999) [@B37]
  Nondiabetic and T2DM subjects            Decreased in T2DM patients                                                       Hotta et al., (2000) [@B28]
  Obese subjects                           Increased after weight loss                                                      Yang et al., (2001) [@B23]
  Caucasians and Pima Indians              Associated with IR                                                               Weyer et al., (2001) [@B153]
  Pima Indian                              Low plasma concentration precedes a decrease in insulin sensitivity              Stefan et al., (2002) [@B29]
  Pima Indian                              Decreased in T2DM patients                                                       Lindsay et al., (2002) [@B30]
  Pima Indian children                     An inverse relationship to adiposity                                             Stefan et al., (2002) [@B154]
  Nondiabetic Japanese women               Negative correlation with serum triglyceride                                     Matsubara et al., (2002) [@B155]
  Obese subjects                           Increased after weight loss                                                      Bruun et al., (2003) [@B24]
  Middle-aged population                   Associated with intra-abdominal fat                                              Cnop et al., (2003) [@B25]
  Nondiabetic white volunteers             Positive correlation with HDL-cholesterol                                        Tschritter et al., (2003) [@B31]
  Hypertensive patients                    Correlation with vasodilator response                                            Ouchi et al., (2003) [@B34]
  Japanese men                             Decreased in patients with CVD                                                   Kumada et al., (2003) [@B38]
  Japanese subjects                        Connected with endothelial dysfunction                                           Shimabukuro et al., (2003) [@B156]
  Japanese subjects                        Decreased in patients with T2DM                                                  Daimon et al., (2003) [@B157]
  Apparently healthy individuals           Associated with the risk of T2DM                                                 Spranger et al., (2003) [@B158]
  Asian Indians with IGT                   Low adiponectin was a strong predictor of T2DM                                   Snehalatha et al., (2003) [@B159]
  Nonobese and obese subjects              Correlation with advantageous lipid profile                                      Baratta et al., (2004) [@B32]
  Japanese men                             Decreased in hypertensive men                                                    Iwashima et al., (2004) [@B33]
  Male participants                        High adiponectin was associated with lower risk of myocardial infarction         Pischon et al., (2004) [@B39]
  Whites and African Americans             Higher adiponectin was associated with a lower incidence of T2DM                 Duncan et al., (2004) [@B160]
  Patients with CVD                        Decreased in patients with CVD                                                   Nakamura et al., (2004) [@B161]
  Pregnant women                           Decreased in patients with gestational DM                                        Ranheim et al., (2004) [@B162]
  Nondiabetic subjects                     Obesity-independent association of IR with adiponectin levels                    Abbasi et al., (2004) [@B163]
  Obese individuals                        Decreased in subjects with MS                                                    Xydakis et al., (2004) [@B164]
  Healthy premenopausal women              Associated with visceral fat mass                                                Kwon et al., (2005) [@B26]
  Obese juveniles                          An inverse relation with the intima media thickness of common carotid arteries   Pilz et al., (2005) [@B40]
  Patients with chronic heart failure      High adiponectin was a predictor of mortality                                    Kistorp et al., (2005) [@B42]
  British women                            No association with CVD risk                                                     Lawlor et al., (2005) [@B43]
  American Indian                          No association with later development of CVD                                     Lindsay et al., (2005) [@B44]
  Hispanic children                        Inversely associated with IR                                                     Butte et al., (2005) [@B52]
  Patients with CVD                        Decreased in patients with CVD                                                   Rothenbacher et al., (2005) [@B165]
  Middle-aged men                          Positive association with lower fat mass                                         Buemann et al., (2005) [@B166]
  Obese children                           Low adiponectin was associated with components of MS                             Winer et al., (2006) [@B36]
  Older Black Americans                    High adiponectin was associated with higher risk of CVD                          Kanaya et al., (2006) [@B45]
  Patients with CVD                        High adiponectin was a predictor of mortality                                    Cavusoglu et al., (2006) [@B46]
  Patients with CVD                        High adiponectin was a predictor of mortality                                    Pilz et al., (2006) [@B50]
  Pregnant women                           Elevated with preeclampsia                                                       Haugen et al., (2006) [@B59]
  Patients with congestive heart failure   Positive correlation with disease severity                                       George et al., (2006) [@B167]
  Caucasian                                High adiponectin increased the risk of death from all causes                     Laughlin et al., (2007) [@B48]
  Aged men                                 High adiponectin increased the risk of death from all causes                     Wannamethee et al., (2007) [@B49]
  Patients with incident CVD               No association with the prognostic outcome                                       von Eynatten et al., (2008) [@B41]
  General Dutch population                 High levels of adiponectin predict mortality                                     Dekker et al., (2008) [@B51]

###### 

Clinical studies of circulating RBP4 levels

  Subjects                               Major findings                                                        References
  -------------------------------------- --------------------------------------------------------------------- ---------------------------------------
  Obese and T2DM subjects                Elevated in subjects with T2DM                                        Yang et al., (2005) [@B66]
  IGT and T2DM subjects                  Correlation with the magnitude of IR                                  Graham et al., (2006) [@B67]
  IGT and T2DM subjects                  Elevated in subjects with IGT or T2DM than normal glucose tolerance   Cho et al., (2006) [@B68]
  Caucasian menopausal women             No correlation with adiposity                                         Janke et al., (2006) [@B72]
  Japanese subjects                      No correlation with BMI                                               Takashima et al., (2006) [@B168]
  IGT and T2DM subjects                  No correlation with IR                                                Erikstrup et al., (2006) [@B169]
  Chinese subjects                       Correlation with the components of MS                                 Qi et al., (2007) [@B69]
  Healthy women                          Associated with visceral fat                                          Lee et al., (2007) [@B70]
  Chinese subjects                       Correlation with visceral adiposity                                   Jia et al., (2007) [@B71]
  Non diabetic person                    No correlation with IR                                                Yao-Borengasser et al., (2007) [@B73]
  Subjects with BMI from 18 to 30        Negative correlation with insulin sensitivity                         Gavi et al., (2007) [@B74]
  Caucasian without T2DM                 Associated with liver fat                                             Stefan et al., (2007) [@B76]
  Nondiabetic individuals                Reflected ectopic fat accumulation                                    Perseghin et al., (2007) [@B77]
  Obese children                         Associated positively with CRP                                        Balagopal et al., (2007) [@B170]
  Subjects with morbid obesity           Reduction after weight loss                                           Haider et al., (2007) [@B171]
  Obese women                            Reduction after weight loss                                           Vitkova et al., (2007) [@B172]
  Patients with T2DM                     Associated with IR                                                    Takebayashi et al., (2007) [@B173]
  Women with polycystic ovary syndrome   Elevated than BMI-matched subjects                                    Tan et al., (2007) [@B174]
  Nondiabetic men                        Negatively associated with insulin secretion                          Broch et al., (2007) [@B175]
  Patients with chronic liver disease    Decreased compared with control subjects                              Yagmur et al., (2007) [@B176]
  Patients with T2DM or CVD              Associated with pro-atherogenic lipoprotein levels                    von Eynatten et al., (2007) [@B177]

###### 

Clinical studies of circulating resistin levels

  Subjects                                                                 Major findings                                        References
  ------------------------------------------------------------------------ ----------------------------------------------------- --------------------------------------------
  Healthy Greek students                                                   Correlation with body fat mass                        Yannakoulia et al., (2003) [@B81]
  Non-diabetic subjects                                                    Correlation with IR                                   Silha et al., (2003) [@B82]
  Patients with essential hypertension                                     Elevated in T2DM patients                             Zhang et al., (2003) [@B83]
  Patients with inflammatory diseases                                      Correlation with inflammatory markers                 Stejskal et al., (2003) [@B91]
  Obese subjects                                                           Correlation with BMI                                  Azuma et al., (2003) [@B178]
  Lean and obese subjects                                                  Increase in obese subjects                            Degawa-Yamauchi et al., (2003) [@B179]
  Women                                                                    No relation with fat mass or IR                       Lee et al., (2003) [@B180]
  Patients with T2DM                                                       No correlation with IR                                Pfutzner et al., (2003) [@B181]
  Obese subjects                                                           Not changed after weight loss                         Monzillo et al., (2003) [@B182]
  Diabetic subjects                                                        Correlation with CRP                                  Shetty et al., (2004) [@B87]
  Obese Caucasian subjects                                                 Correlation with HOMA-R                               Silha et al., (2004) [@B183]
  Non obese subjects                                                       Correlation with insulin sensitivity                  Heilbronn et al., (2004) [@B184]
  Pima Indians                                                             Correlation with fat mass but not IR                  Vozarova de Courten et al., (2004) [@B185]
  Diabetic subjects                                                        Elevated in T2DM patients                             Youn et al., (2004) [@B186]
  Japanese subjects                                                        Elevated in T2DM patients                             Fujinami et al., (2004) [@B187]
  Patients with T2DM                                                       Correlation with hepatic fat content                  Bajaj et al., (2004) [@B188]
  Women                                                                    Associated with the presence of CVD                   Pischon et al., (2005) [@B88]
  Subjects who had a family history of premature coronary artery disease   Correlation with the levels of inflammatory markers   Reilly et al., (2005) [@B90]
  Japanese subjects                                                        Associated with the presence and severity of CVD      Ohmori et al., (2005) [@B189]
  Men                                                                      Correlation with CRP                                  Bo et al., (2005) [@B190]
  Patients with rheumatoid arthritis                                       Elevated than the patients with osteoarthritis        Senolt et al., (2007) [@B89]

###### 

Clinical studies of circulating inflammatory markers

  Subjects                                      Major findings                                                  References
  --------------------------------------------- --------------------------------------------------------------- -----------------------------------------
  TNFα                                                                                                          
  Nondiabetic offsprings of T2DM patients       Not major contributing factor for obesity induced IR            Kellerer et al., (1996) [@B97]
  Adult males                                   Elevated in patients with T2DM                                  Pfeiffer et al., (1997) [@B96]
  Obese patients with T2DM                      Correlation with the visceral fat area                          Katsuki et al., (1998) [@B191]
  T2DM subjects                                 Elevated in T2DM as compared to control                         Winkler et al., (1998) [@B192]
  Aged men                                      Correlation with BMI                                            Nilsson et al., (1998) [@B193]
  Canadian population                           Positive correlation with IR                                    Zinman et al., (1999) [@B194]
  Obese subjects                                Elevated in obese subjects than in controls                     Corica et al., (1999) [@B195]
  Normotensive obese patients                   Elevated in patients with android obesity than gynoid obesity   Winkler et al., (1999) [@B196]
  Obese subjects                                No relationship with BMI                                        Kern et al., (2001) [@B98]
  Premenopausal obese women                     Reduced after weight loss                                       Ziccardi et al., (2002) [@B197]
  Nondiabetic obese women                       Associated with fat amount                                      Maachi et al., (2004) [@B198]
  Premenopausal obese women                     Reduced after weight loss                                       Marfella et al., (2004) [@B199]
                                                                                                                
  IL-6                                                                                                          
  White nondiabetic subjects                    Correlation with BMI                                            Yudkin et al., (1999) [@B100]
  Healthy middle-aged women                     Associated with BMI                                             Hak et al., (1999) [@B200]
  Obese nondiabetic women                       Reduced after weight loss                                       Bastard et al., (2000) [@B103]
  Obese subjects                                Correlation with obesity and IR                                 Kern et al., (2001) [@B98]
  Pima Indians                                  Correlation with IR                                             Vozarova et al., (2001) [@B102]
  Premenopausal obese women                     Reduced after weight loss                                       Ziccardi et al., (2002) [@B197]
  Premenopausal obese women                     Reduced after weight loss                                       Esposito et al., (2003) [@B104]
  Obese patients                                Reduced after weight loss                                       Kopp et al., (2003) [@B105]
  Obese subjects                                Reduced after weight loss                                       Monzillo et al., (2003) [@B182]
  Premenopausal obese women                     Reduced after weight loss                                       Giugliano et al., (2004) [@B106]
  Nondiabetic offspring of patients with T2DM   Not associated with the components of MS                        Salmenniemi et al., (2004) [@B110]
  Premenopausal obese women                     Reduced after weight loss                                       Marfella et al., (2004) [@B199]
  Japanese men                                  Not associated with the components of MS                        Matsushita et al., (2006) [@B111]
  T2DM subjects                                 Associated with IR                                              Natali et al., (2006) [@B201]
  Adolescents                                   Positive correlation with BMI                                   Herder et al., (2007) [@B135]
                                                                                                                
  CRP                                                                                                           
  White nondiabetic subjects                    Positive correlation with BMI                                   Yudkin et al., (1999) [@B100]
  Healthy middle-aged women                     Associated with BMI                                             Hak et al., (1999) [@B200]
  Young adults                                  Elevated in obese person                                        Visser et al., (1999) [@B202]
  Adult men                                     Correlation with body fat mass                                  Lemieux et al., (2001) [@B115]
  Obese women                                   Reduced after weight loss                                       Heilbronn et al., (2001) [@B117]
  Middle-aged men                               Predictor of T2DM development                                   Freeman et al., (2002) [@B116]
  Obese postmenopausal women                    Reduced after weight loss                                       Tchernof et al., (2002) [@B118]
  Premenopausal obese women                     Reduced after weight loss                                       Ziccardi et al., (2002) [@B197]
  Healthy obese women                           Correlation with IR independent of obesity                      McLaughlin et al., (2002) [@B203]
  Premenopausal obese women                     Reduced after weight loss                                       Esposito et al., (2003) [@B104]
  Healthy American women                        Prognostic marker to the MS                                     Ridker et al., (2003) [@B114]
  Premenopausal obese women                     Obesity is the major determinant of elevated CRP levels         Escobar-Morreale et al., (2003) [@B204]
  Premenopausal obese women                     Reduced after weight loss                                       Marfella et al., (2004) [@B199]
  Obese subjects                                Correlation with serum TNFα levels                              Shadid et al., (2006) [@B86]
  T2DM subjects                                 Associated with IR                                              Natali et al., (2006) [@B201]
  Overweight women                              Reduced after weight loss                                       Moran et al., (2007) [@B205]
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